Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1761-1780 of 3,900 trials

Interstitial Lung Disease: Rituximab and Mycophenolate Combination

We are studying a combination of rituximab and mycophenolate mofetil for patients with interstitial lung disease related to systemic sclerosis. The goal is to see if this treatment improves lung function and overall health compared to a placebo.

Lung Involvement in Systemic Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesPulmonologyRheumatology

Tau Imaging in Alzheimer's: Comparing PET Tracers

We are comparing three different PET tau tracers in volunteers to see which one best measures tau levels in the brain. This research may help improve diagnosis and treatment monitoring for Alzheimer's disease.

Cognitive Impairment>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOtolaryngology

Acute Myeloid Leukemia: KO-539 Treatment Study

We are testing a new drug called KO-539 in patients with relapsed or refractory acute myeloid leukemia. The goal is to see if it is safe and effective for those with specific genetic mutations.

Relapsed Acute Myeloid Leukemia≤3 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Solid Tumors: DF6002 Treatment Study

We are investigating the safety and effectiveness of DF6002, alone and with Nivolumab, for patients with advanced solid tumors. This study aims to find the best dose and understand how well the treatment works.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesOncology

High-Risk Myelodysplastic Syndromes: Stem Cell Transplantation Study

We are evaluating a new treatment approach that combines hypomethylating therapy with stem cell transplantation for patients with high-risk myelodysplastic syndromes. The study aims to assess the feasibility and safety of this combined treatment.

Myelodysplastic SyndromeConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology

B-Cell Acute Lymphoblastic Leukemia: Inotuzumab Ozogamicin Study

We are examining whether Inotuzumab can help adults with B-Cell Acute Lymphoblastic Leukemia achieve MRD negativity before stem cell transplantation. The study will also look at treatment safety and survival rates.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Obstructive Sleep Apnea: Sulthiam and Oral Appliance Study

We are studying whether adding the medication sulthiam to an oral appliance helps patients with obstructive sleep apnea who aren't getting enough relief from their current treatment. This trial will also look for specific biomarkers related to their condition.

Obstructive Sleep ApneaEfficacy phase (II)Investigational MedicinesInternal MedicinePulmonology

Mucositis Prevention: Dexpanthenol Mouth Rinse

We are studying whether a new mouth rinse can help reduce mouth sores in patients receiving radiation therapy. The trial compares this rinse to a placebo to see if it improves comfort and quality of life.

Radiation-Induced Oral Mucositis>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatologyOncologyOtolaryngology

ANCA-Associated Vasculitis: LNP023 (iptacopan) Study

We are testing a new treatment for patients with active ANCA-associated vasculitis to see if it helps achieve lasting remission compared to standard care. The study will also evaluate its impact on disease relapse and kidney health.

Microscopic PolyangiitisGranulomatosis with Polyangiitis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Targeted Anti-Cancer Treatment: ProTarget Trial

We are studying how effective and safe targeted cancer drugs are for patients with advanced cancer and specific genetic markers. This research may help improve treatment options based on individual genetic profiles.

Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Brain Health: [11C]HSP990 PET Imaging

We are investigating a new imaging agent to measure Hsp90 levels in the brains of healthy individuals and those with neurodegeneration. This study aims to improve our understanding of brain aging and related diseases.

Alzheimer's DiseaseAmyotrophic Lateral SclerosisParkinson's Disease>2 yearsSafety phase (I)NeurologyOtolaryngology

Metastatic Prostate Cancer: Talazoparib and Enzalutamide Study

We are testing a combination of Talazoparib and Enzalutamide for patients with metastatic prostate cancer who have progressed after abiraterone. The study aims to evaluate its effectiveness and safety as a first-line treatment.

Metastatic Prostate CancerEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

B-cell Malignancies: NX-5948 Treatment Study

We are testing NX-5948 in adults with relapsed or refractory B-cell malignancies. The goal is to see if this new treatment can help those who have not responded to other therapies.

Relapsed/Refractory B-cell Malignancies>2 yearsSafety phase (I)Oncology

Melanoma: Direct Tumor Treatment with Microdosing

We are exploring a new way to deliver treatment directly into tumors for patients with advanced melanoma on anti-PD1 therapy. This pilot study aims to see if this method improves outcomes.

Malignant Melanoma>2 yearsSafety phase (I)DermatologyOncology

Non-Alcoholic Steatohepatitis: Namodenoson Study

We are testing a new oral medication, namodenoson, for individuals with Non-Alcoholic Steatohepatitis (NASH). The study aims to see if it improves liver health and to evaluate its safety.

Non-Alcoholic Steatohepatitis (NASH)6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

Head and Neck Cancer: New Treatment Combinations

We are comparing a new drug combination with a single drug for patients with locally advanced head and neck cancer. The aim is to see which treatment works better before starting chemoradiotherapy.

Locally Advanced Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Vitamin C Treatment for Cardiac Surgery Patients

We are studying whether vitamin C can reduce inflammation and improve recovery in patients undergoing cardiac surgery. This trial compares vitamin C treatment to standard care to see which is more effective.

Cardiovascular Illness>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Inhaled Therapy for High-Risk Thoracic Surgery Patients

We are studying whether using a bronchodilator before and after surgery helps reduce lung complications in patients at high risk. This trial will also look at other health outcomes and quality of life after surgery.

Postoperative Pulmonary ComplicationsConfirmation phase (III)Standard MedicinesPartially RemotePulmonology

Advanced Solid Tumors: MOST Plus Treatment Study

We are studying a new maintenance treatment for patients with advanced solid tumors to see if it helps keep the disease stable after initial therapy. This trial compares ongoing treatment with stopping the therapy to understand the best approach.

Advanced or Metastatic Cancers>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Cancer: Targeted Therapy Study

We are evaluating new treatments that specifically target the molecular changes in tumors of patients with advanced or metastatic cancer. The goal is to see how well these therapies work and their safety profile.

Advanced / Metastatic Cancers>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology